Hospital
ST Francis Hospital INC
ST Francis Hospital INC was paid $17.81M by Medicaid between Jan 2018 and Dec 2024, across 270 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 16% of everything it billed.
33Billing provider infoST FRANCIS HOSPITAL INC
GREENVILLE, SC 29601
GREENVILLE, SC 29601
33aNPI1730123175assigned 06/16/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$17.81M
24GClaims768,210
24DCodes billed270
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#20 of 115
Median peer was paid$2.47M
This provider vs. median7.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RALSTON, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 97,110 | $1.87M | |
| 2019 | 91,052 | $1.53M | |
| 2020 | 73,086 | $1.41M | |
| 2021 | 110,580 | $2.26M | |
| 2022 | 139,200 | $3.85M | |
| 2023 | 124,782 | $3.86M | |
| 2024incomplete | 132,400 | $3.02M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 16% | 41,807 | 33,873 | $2.88M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 35,230 | 30,412 | $1.89M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 7.5% | 14,681 | 12,377 | $1.34M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.3% | 6,510 | 5,577 | $771K |
| 80048 | Basic metabolic panel (calcium, ionized) | 4.1% | 12,241 | 8,804 | $727K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 3.9% | 3,315 | 3,177 | $698K |
| 82962 | 3.7% | 16,848 | 7,029 | $654K | |
| 36415 | Collection of venous blood by venipuncture | 3.1% | 16,288 | 10,987 | $555K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.6% | 8,905 | 6,205 | $467K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.0% | 7,961 | 7,063 | $365K |
| 81025 | 1.8% | 11,424 | 10,135 | $327K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.8% | 2,694 | 2,545 | $319K |
258 more codes
| 99284 | Emergency room visit (serious) | 1.7% | 30,692 | $295K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.6% | 3,932 | $283K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 10,412 | $279K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.5% | 8,773 | $265K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.3% | 353 | $232K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 3,841 | $225K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.2% | 4,988 | $222K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 13,529 | $208K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.2% | 3,229 | $207K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 1,520 | $199K |
| 81001 | 1.1% | 12,748 | $197K | |
| 87210 | 1.1% | 2,213 | $189K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.0% | 1,289 | $184K |
| 81003 | <1% | 13,115 | $168K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,042 | $161K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 6,308 | $144K |
| 73562 | <1% | 2,613 | $129K | |
| 73610 | <1% | 1,241 | $129K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,717 | $122K |
| 93971 | <1% | 1,308 | $120K | |
| 82565 | <1% | 1,566 | $120K | |
| 84132 | <1% | 2,361 | $118K | |
| 86900 | <1% | 1,866 | $113K | |
| 73630 | <1% | 1,650 | $111K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,634 | $103K |
| 72100 | <1% | 2,835 | $103K | |
| 73030 | <1% | 1,800 | $97K | |
| 99285 | Emergency room visit (most serious) | <1% | 18,164 | $95K |
| 84702 | <1% | 1,606 | $92K | |
| 73130 | <1% | 829 | $88K | |
| 87081 | <1% | 847 | $84K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,373 | $80K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 4,966 | $68K |
| 71250 | <1% | 496 | $67K | |
| 73110 | <1% | 529 | $62K | |
| 71045 | Radiologic examination, chest; single view | <1% | 9,999 | $62K |
| 87040 | <1% | 3,554 | $58K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 46,338 | $53K |
| 93458 | <1% | 359 | $52K | |
| 72040 | <1% | 1,225 | $51K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 512 | $48K |
| 96376 | <1% | 3,892 | $44K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 6,587 | $43K |
| G0378 | Hospital observation service, per hour | <1% | 9,187 | $40K |
| 87186 | <1% | 1,734 | $37K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 133 | $35K |
| 73502 | <1% | 1,462 | $34K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 468 | $31K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 831 | $30K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 896 | $29K |
| 85018 | <1% | 1,206 | $29K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,332 | $28K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 253 | $27K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,763 | $24K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,914 | $23K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 19,705 | $23K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,556 | $23K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 218 | $23K |
| 80050 | General health panel | <1% | 705 | $22K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 500 | $22K |
| 74018 | <1% | 572 | $22K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 733 | $21K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 10,788 | $19K |
| 84484 | <1% | 19,039 | $19K | |
| 87807 | <1% | 99 | $18K | |
| C1769 | Guide wire | <1% | 2,456 | $18K |
| 87070 | <1% | 416 | $17K | |
| 97161 | <1% | 1,245 | $16K | |
| 85027 | <1% | 7,240 | $16K | |
| 85610 | <1% | 3,845 | $15K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 968 | $14K |
| 76830 | Ultrasound, transvaginal | <1% | 244 | $12K |
| 74022 | <1% | 1,144 | $12K | |
| 81015 | <1% | 1,149 | $12K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 799 | $11K |
| 83735 | <1% | 12,369 | $11K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,630 | $11K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,932 | $10K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 36 | $10K |
| J2704 | Injection, propofol, 10 mg | <1% | 10,890 | $10K |
| 12001 | <1% | 67 | $9K | |
| 95811 | <1% | 42 | $9K | |
| 87634 | <1% | 293 | $9K | |
| 94760 | <1% | 2,312 | $9K | |
| 82077 | <1% | 1,793 | $8K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 180 | $8K |
| 97162 | <1% | 584 | $8K | |
| 70486 | <1% | 59 | $7K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 327 | $7K |
| J3490 | Unclassified drugs | <1% | 3,958 | $7K |
| 95806 | <1% | 58 | $6K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,202 | $6K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,439 | $6K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,088 | $6K |
| 93970 | <1% | 28 | $6K | |
| 80061 | Lipid panel | <1% | 3,532 | $6K |
| 73080 | <1% | 46 | $5K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,291 | $5K |
| 88304 | <1% | 92 | $5K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 2,087 | $5K |
| 83690 | <1% | 14,280 | $4K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 13 | $4K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,195 | $4K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 57 | $4K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 13,580 | $4K |
| 83605 | <1% | 5,906 | $4K | |
| 85379 | <1% | 2,506 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,837 | $4K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,917 | $4K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,504 | $4K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 13 | $4K |
| 73590 | <1% | 112 | $4K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 418 | $4K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 517 | $4K |
| 83880 | <1% | 4,321 | $3K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 378 | $3K |
| 70496 | <1% | 111 | $3K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 832 | $3K |
| J1815 | Injection, insulin, per 5 units | <1% | 460 | $3K |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,120 | $3K |
| 86850 | <1% | 1,222 | $3K | |
| 10060 | <1% | 30 | $3K | |
| 80047 | <1% | 63 | $3K | |
| 85652 | <1% | 668 | $2K | |
| 80179 | <1% | 318 | $2K | |
| 99152 | <1% | 2,429 | $2K | |
| 86140 | <1% | 1,732 | $2K | |
| 74019 | <1% | 55 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,752 | $2K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 295 | $2K |
| 80143 | <1% | 310 | $2K | |
| 86592 | <1% | 340 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,574 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,136 | $2K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 390 | $2K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,347 | $2K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 371 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,268 | $2K |
| 77001 | <1% | 12 | $2K | |
| A4565 | Slings | <1% | 59 | $1K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 2,223 | $1K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 351 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,322 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,653 | $1K |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 899 | $1K |
| 86780 | <1% | 174 | $1K | |
| 74230 | <1% | 13 | $1K | |
| 87340 | <1% | 340 | $977.54 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 830 | $942.01 |
| 94761 | <1% | 452 | $901.29 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,554 | $891.83 |
| 82728 | <1% | 358 | $886.49 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 505 | $821.77 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 274 | $788.05 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,905 | $775.19 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,181 | $765.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,104 | $758.88 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 508 | $753.35 |
| 84145 | <1% | 2,356 | $735.55 | |
| 72070 | <1% | 29 | $678.87 | |
| 82570 | <1% | 467 | $673.32 | |
| 84100 | <1% | 81 | $653.54 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 118 | $610.18 |
| 97165 | <1% | 412 | $594.24 | |
| 84550 | <1% | 213 | $583.35 | |
| 86803 | <1% | 876 | $533.87 | |
| 73090 | <1% | 12 | $462.68 | |
| 82803 | <1% | 330 | $446.92 | |
| 76770 | <1% | 13 | $443.19 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,813 | $411.76 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 407 | $405.68 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 552 | $403.14 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,648 | $383.27 |
| 87088 | <1% | 1,179 | $337.54 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,094 | $323.48 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,980 | $306.83 |
| 84703 | <1% | 33 | $217.48 | |
| 84439 | <1% | 874 | $164.41 | |
| 96367 | <1% | 14 | $91.85 | |
| 94762 | <1% | 1,182 | $81.15 | |
| 76801 | <1% | 58 | $78.42 | |
| 82043 | <1% | 247 | $77.98 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 12 | $76.50 |
| 82607 | <1% | 398 | $71.36 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 685 | $68.35 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 696 | $50.00 |
| 90714 | <1% | 225 | $37.93 | |
| 76937 | <1% | 541 | $35.96 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 1,717 | $35.18 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 29 | $27.91 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 132 | $23.29 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,030 | $9.54 |
| 86901 | <1% | 1,867 | $7.87 | |
| 82550 | <1% | 595 | $5.86 | |
| A9270 | Non-covered item or service | <1% | 331 | $1.32 |
| 80081 | 0% | 40 | $0.00 | |
| 87205 | 0% | 570 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 344 | $0.00 |
| 85730 | 0% | 279 | $0.00 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 13 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 125 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 950 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 65 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 308 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 1,794 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 29 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 380 | $0.00 |
| 70498 | 0% | 121 | $0.00 | |
| 86141 | 0% | 104 | $0.00 | |
| 90686 | 0% | 27 | $0.00 | |
| 84153 | 0% | 51 | $0.00 | |
| 86762 | 0% | 49 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 25 | $0.00 |
| 80055 | 0% | 107 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 63 | $0.00 |
| 83550 | 0% | 34 | $0.00 | |
| 86580 | 0% | 30 | $0.00 | |
| J2305 | Injection, nitroglycerin, 5 mg | 0% | 36 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 53 | $0.00 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 49 | $0.00 |
| J2372 | Injection, phenylephrine hydrochloride (biorphen), 20 micrograms | 0% | 12 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 36 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 17 | $0.00 |
| 83615 | 0% | 16 | $0.00 | |
| 36430 | 0% | 17 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 18 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 12 | $0.00 |
| 82746 | 0% | 15 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 329 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 314 | $0.00 |
| 94664 | 0% | 245 | $0.00 | |
| 76942 | 0% | 395 | $0.00 | |
| 83540 | 0% | 402 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 125 | $0.00 |
| 88312 | 0% | 547 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 114 | $0.00 |
| 80076 | 0% | 273 | $0.00 | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | 0% | 235 | $0.00 |
| 36600 | 0% | 102 | $0.00 | |
| 90715 | 0% | 187 | $0.00 | |
| 86038 | 0% | 14 | $0.00 | |
| 83020 | 0% | 80 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 203 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 365 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 141 | $0.00 |
| 80074 | 0% | 12 | $0.00 | |
| 43235 | 0% | 26 | $0.00 | |
| 82140 | 0% | 13 | $0.00 | |
| 92611 | 0% | 12 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 62 | $0.00 |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | 0% | 49 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 18 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 12 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 33 | $0.00 |
| 84156 | 0% | 14 | $0.00 | |
| 92610 | 0% | 29 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 27 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRALSTON, KIMBERLY (VP REIMBURSEMENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.